References
- Lamprecht P , KersteinA, KlapaSet al. Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front. Immunol.9(4), 680–689 (2018).
- Panaput T , ThinkhamropB, DomrongkitchaipornSet al. Dialysis dose and risk factors for death among ESRD patients treated with twice-weekly hemodialysis: a prospective cohort study. Blood Purif.38(3), 253–262 (2014).
- Sridhar NR , JosyulaS. Hypoalbuminemia in hemodialyzed end stage renal disease patients: risk factors and relationships a 2-year single center study. BMC Nephrol.14(1), 242–250 (2013).
- Porrett M , BaranovE, TerHM. Serum hypoalbuminemia predicts late mortality on the liver transplant waiting list. Transplantation99(1), 158–163 (2015).
- Papachristou NI , BlairHC, KypreosKE, PapachristouDJ. High-density lipoprotein (HDL) metabolism and bone mass. J. Endocrinol.233(2), 95–107 (2017).
- Jennette JC , FalkRJ, BaconPAet al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheumatol.65(1), 1–11 (2013).
- Berden A , GöçerogluA, JayneDet al. Diagnosis and management of ANCA associated vasculitis. BMJ344(2), 321–346 (2012).
- Li ZY , MaTT, ChenM, ZhaoMH. The prevalence and management of anti-neutrophil cytoplasmic antibody-associated vasculitis in China. Kidney Dis. (Basel)1(4), 216–223 (2016).
- Vavrova L , RychlikovaJ, MrackovaM, NovakovaO, ZakA, NovakF. Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin. Clin. Exp. Med.16(4), 557–569 (2016)
- Xu PC , TongZY, ChenTet al. Hypoalbuminaemia in antineutrophil cytoplasmic antibody-associated vasculitis: incidence and significance. Clin. Exp. Rheumatol.36(4), 603–611 (2018).
- Yang L , XieH, LiuZet al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol.19(1), 138–144 (2018).
- Corsonello A , PedoneC, BattagliaS, PaglinoG, BelliaV, IncalziRA. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). Arch. Gerontol. Geriatr.53(2), 190–195 (2011).
- Okemefuna AI , NanR, MillerA, GorJ, PerkinsSJ. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem.47(13), 2263–2264 (2010).
- Miller GJ , MillerNE. Plasma high-density lipoprotein concentration and development of ischaemic heart-disease. Lancet1(1), 16–19 (1975).
- Constantinou C , KaraviaEA, XepapadakiEet al. Advances in high-density lipoprotein physiology: surprises, overturns, and promises. Am. J. Physiol. Endocrinol. Metab.310(1), 1–14 (2016).
- Moein Moghimi S , HamadI, BüngerRet al. Activation of the human complement system by cholesterol-rich and PEGylated liposomes- modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J. Liposome Res.16(3), 167–174 (2006).
- Moghimi SM , HunterAC, DadswellCM, SavayS, AlvingCR, SzebeniJ. Causative factors behind poloxamer 188 (pluronic F68, flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta1689(2), 103–113 (2004).
- Norata GD , MarchesiP, PirilloAet al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol.28(5), 925–931 (2008).
- Undurti A , HuangY, LupicaJA, SmithJD, DiDonatoJA, HazenL. Modification of high density lipoprotein by myeloperoxidase generates a proinflammatory particle. J. Biol. Chem.284(45), 30825–30835 (2009).